Literature DB >> 25377784

Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

Juhi Ojha1, Jackline Ayres2, Charla Secreto3, Renee Tschumper3, Kari Rabe3, Daniel Van Dyke3, Susan Slager3, Tait Shanafelt3, Rafael Fonseca1, Neil E Kay3, Esteban Braggio1.   

Abstract

Recent high-throughput sequencing and microarray studies have characterized the genetic landscape and clonal complexity of chronic lymphocytic leukemia (CLL). Here, we performed a longitudinal study in a homogeneously treated cohort of 12 patients, with sequential samples obtained at comparable stages of disease. We identified clonal competition between 2 or more genetic subclones in 70% of the patients with relapse, and stable clonal dynamics in the remaining 30%. By deep sequencing, we identified a high reservoir of genetic heterogeneity in the form of several driver genes mutated in small subclones underlying the disease course. Furthermore, in 2 patients, we identified convergent evolution, characterized by the combination of genetic lesions affecting the same genes or copy number abnormality in different subclones. The phenomenon affects multiple CLL putative driver abnormalities, including mutations in NOTCH1, SF3B1, DDX3X, and del(11q23). This is the first report documenting convergent evolution as a recurrent event in the CLL genome. Furthermore, this finding suggests the selective advantage of specific combinations of genetic lesions for CLL pathogenesis in a subset of patients.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25377784      PMCID: PMC4296010          DOI: 10.1182/blood-2014-06-580563

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.

Authors:  S Molica; D Levato; A Dattilo
Journal:  Haematologica       Date:  1999-12       Impact factor: 9.941

2.  What is changing in the natural history of chronic lymphocytic leukemia?

Authors:  S Molica; D Levato
Journal:  Haematologica       Date:  2001-01       Impact factor: 9.941

3.  The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.

Authors:  L F Diehl; L H Karnell; H R Menck
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

4.  Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Authors:  E Braggio; N E Kay; S VanWier; R C Tschumper; S Smoley; J E Eckel-Passow; T Sassoon; M Barrett; D L Van Dyke; J C Byrd; D F Jelinek; T D Shanafelt; R Fonseca
Journal:  Leukemia       Date:  2012-01-20       Impact factor: 11.528

5.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

6.  Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

Authors:  T G Call; R L Phyliky; P Noël; T M Habermann; C M Beard; W M O'Fallon; L T Kurland
Journal:  Mayo Clin Proc       Date:  1994-04       Impact factor: 7.616

7.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

8.  Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.

Authors:  D Catovsky; J Fooks; S Richards
Journal:  Br J Haematol       Date:  1989-06       Impact factor: 6.998

9.  Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.

Authors:  J Ojha; C Secreto; K Rabe; J Ayres-Silva; R Tschumper; D V Dyke; S Slager; R Fonseca; T Shanafelt; N Kay; E Braggio
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

10.  Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.

Authors:  S J L Knight; C Yau; R Clifford; A T Timbs; E Sadighi Akha; H M Dréau; A Burns; C Ciria; D G Oscier; A R Pettitt; S Dutton; C C Holmes; J Taylor; J-B Cazier; A Schuh
Journal:  Leukemia       Date:  2012-01-19       Impact factor: 11.528

View more
  23 in total

Review 1.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Romain Guièze; Catherine J Wu
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 3.  Molecular pathogenesis of CLL and its evolution.

Authors:  David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

4.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

Review 5.  A population genetics perspective on the determinants of intra-tumor heterogeneity.

Authors:  Zheng Hu; Ruping Sun; Christina Curtis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-06       Impact factor: 10.680

6.  Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Authors:  Michaela Gruber; Ivana Bozic; Ignaty Leshchiner; Dimitri Livitz; Kristen Stevenson; Laura Rassenti; Daniel Rosebrock; Amaro Taylor-Weiner; Oriol Olive; Reaha Goyetche; Stacey M Fernandes; Jing Sun; Chip Stewart; Alicia Wong; Carrie Cibulskis; Wandi Zhang; Johannes G Reiter; Jeffrey M Gerold; John G Gribben; Kanti R Rai; Michael J Keating; Jennifer R Brown; Donna Neuberg; Thomas J Kipps; Martin A Nowak; Gad Getz; Catherine J Wu
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

7.  Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.

Authors:  Ilaria Del Giudice; Marilisa Marinelli; Jiguang Wang; Silvia Bonina; Monica Messina; Sabina Chiaretti; Caterina Ilari; Luciana Cafforio; Sara Raponi; Francesca Romana Mauro; Valeria Di Maio; Maria Stefania De Propris; Mauro Nanni; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Anna Guarini; Raul Rabadan; Robin Foà
Journal:  Br J Haematol       Date:  2015-11-24       Impact factor: 6.998

8.  A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.

Authors:  Nisar A Amin; Erlene Seymour; Kamlai Saiya-Cork; Brian Parkin; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

Review 9.  A river model to map convergent cancer evolution and guide therapy in RCC.

Authors:  Elizabeth Y Wei; James J Hsieh
Journal:  Nat Rev Urol       Date:  2015-11-03       Impact factor: 14.432

10.  An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

Authors:  L Worrillow; P Baskaran; M A Care; A Varghese; T Munir; P A Evans; S J O'Connor; A Rawstron; L Hazelwood; R M Tooze; P Hillmen; D J Newton
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.